AMG133 peptide payload TFA
Based on 1 Customer Validation
AMG133 peptide payload TFA is a GLP-1 analog agonist peptide. AMG133 peptide payload TFA potently activates GLP-1R and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload TFA can be used for the synthesis of AMG 133 (HY-164535).
For research use only. We do not sell to patients.
- Purity: 99.68%
- Formula: C196H290BrN55O69.xC2HF3O2
- Molecular Weight:4600.70 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
AMG133 is a potent GLP-1R agonist, with EC50 values of 24.4 pM, 5.7 pM, 123 pM and 2.4 pM against human GLP-1R, cynomolgus monkey GLP-1R, mouse GLP-1R and rat GLP-1R, respectively[1].
AMG133 acts as a GIPR antagonist, with IC50 values of 42.4 nM, 26.5 nM, and 822.3 nM against human GIPR, cynomolgus monkey GIPR, and rat GIPR, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
AMG 133 murine surrogate (0.5-2.5 mg/kg; i.p.; every 6 days; 3 doses total) produces sustained, dose-dependent body weight loss, reduced food intake, and improved metabolic parameters in diet-induced obese male mice[1].
AMG133 (0.25-0.75 mg/kg; s.c.; once weekly; 6 weeks) reduces body weight in obese male cynomolgus monkeys by 11% and 13% relative to baseline levels, respectively, while also decreasing energy intake and improving metabolic markers[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N (male, 22 weeks of age, diet-induced obese)[1]
-
Dosage:0.5 mg/kg; 2.5 mg/kg
-
Administration:i.p.; every 6 days; 18 days
-
Result:Produced significant body weight loss from day 1 through day 18, with a dose-dependent effect.
Reduced food intake in a dose-proportional manner, with the most pronounced reduction observed on days 0-3.
Induced significant decreases in blood glucose, plasma insulin, triglycerides, and total cholesterol compared to controls.
-
Animal Model:Macaca fascicularis (male, BMI > 41 kg/m2, spontaneous obese)[1]
-
Dosage:0.25 mg/kg; 0.75 mg/kg
-
Administration:s.c.; once weekly; 6 weeks
-
Result:Reduced body weight by 11% (0.25 mg/kg dose) and 13% (0.75 mg/kg dose) from baseline after 6 weeks of treatment.
Observed dose-dependent reduction in total energy intake in the first 3 weeks of dosing.
Significantly reduced fasting triglycerides, fasting insulin, total cholesterol, and low-density lipoprotein cholesterol levels from baseline in both dose groups.
Chemical Information
-
Appearance Solid
-
Molecular Weight 4600.70 (free base)
-
Formula C196H290BrN55O69.xC2HF3O2
-
Color White to off-white
-
Sequence
His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ser-Tyr-Leu-Glu-Glu-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Lys(BrAc)-NH2
-
Sequence Shortening
H-{Aib}-EGTFTSDYSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGS-Lys(BrAc)-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : ≥ 50 mg/mL
* "≥" means soluble, but saturation unknown.
Purity & Documentation
-
Data Sheet (294 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)